Form 4: Y-mAbs Executive's Options Cashed Out in Merger

Y-mAbs Therapeutics SVP Douglas J. Gentilcore's stock options were converted to cash following the company's merger on September 16, 2025.

Summary

• Douglas J. Gentilcore, SVP, Danyelza Bus. Unit Head at Y-mAbs Therapeutics, Inc., reported the disposition of his employee stock options.
• Y-mAbs Therapeutics, Inc. completed a merger on September 16, 2025, becoming an indirect wholly-owned subsidiary of Perseus BidCo US, Inc. (Parent) and Stark International Lux (Ultimate Parent), following a tender offer by Yosemite Merger Sub, Inc. (Purchaser).
• The merger consideration was $8.60 per share in cash.
• Gentilcore's 142,600 employee stock options, with an exercise price of $6.16 per share, were cancelled and converted into a cash payment.
• The cash received for these options was calculated as ($8.60 $6.16) * 142,600 shares, totaling $347,944.
• Options with an exercise price equal to or exceeding the $8.60 merger consideration were cancelled for no consideration.
• Gentilcore is no longer subject to Section 16 reporting obligations for Y-mAbs Therapeutics, Inc. as a result of the merger.

Sentiment

Score: 7

Explanation: The filing reports the expected and positive outcome for an executive's stock options following a completed merger, indicating a successful liquidity event for the option holder. It is neutral for the company as it is now private.

Positives

• The reporting person received a cash payment for their in-the-money stock options, providing liquidity.
• The completion of the merger provides a definitive exit and liquidity event for Y-mAbs Therapeutics, Inc. shareholders and option holders.

Negatives

• Y-mAbs Therapeutics, Inc. is no longer an independent publicly traded company.
• Any stock options with an exercise price equal to or greater than the $8.60 merger consideration were cancelled without any payment.

Future Outlook

The filing indicates the completion of a merger, resulting in Y-mAbs Therapeutics, Inc. becoming an indirect wholly-owned subsidiary of Parent. As such, there are no forward-looking statements or guidance provided for the now-private company in this Form 4.

Industry Context

This transaction is characteristic of the biotechnology and pharmaceutical sectors, where smaller companies with specialized assets or pipelines are frequently acquired by larger entities. The acquisition of Y-mAbs Therapeutics, Inc. by Perseus BidCo US, Inc. and Stark International Lux, with the subsequent cashing out of executive stock options, aligns with typical M&A activity in the industry, providing an exit for public investors and integrating the acquired company's assets, such as the Danyelza business unit, into a broader corporate structure.

Comparison to Industry Standards

• The conversion of in-the-money stock options into cash at the difference between the merger consideration and the exercise price is a standard practice in corporate acquisitions, consistent with industry benchmarks for executive compensation and M&A terms.
• The merger consideration of $8.60 per share would typically be evaluated against the company's pre-merger trading price, analyst price targets, and valuations of comparable biotech acquisitions, considering factors like Y-mAbs's clinical pipeline, regulatory approvals (e.g., Danyelza), and market position. Without specific financial details of Y-mAbs or comparable transactions, a detailed assessment of the premium or valuation is not possible from this filing alone.

Management Changes

Related Party Transactions

• The cancellation and cash conversion of employee stock options for Douglas J. Gentilcore, an SVP of Y-mAbs Therapeutics, Inc., as part of the merger agreement, constitutes a related party transaction.

Stakeholder Impact

• Shareholders of Y-mAbs Therapeutics, Inc. received $8.60 per share in cash for their common stock.
• Option holders, including the reporting person, received cash for their in-the-money options, providing a liquidity event.
• Employees of Y-mAbs Therapeutics, Inc. will now operate under new ownership as the company continues as a subsidiary, potentially impacting corporate culture and strategic direction.

Key Dates

Keywords

Y-mAbs Therapeutics, YMAB, Merger, Stock Options, Insider Transaction, Form 4, Acquisition, Douglas J. Gentilcore, Danyelza